首页 > 最新文献

International journal of hematology-oncology and stem cell research最新文献

英文 中文
Transduction of Human Fetal Liver Hematopoietic CD34+ Stem and Progenitor Cells into a Cell Line by Enhancing Telomerase Activity. 通过增强端粒酶活性将人胎儿肝造血CD34+干细胞和祖细胞转导成细胞系。
Pub Date : 2024-10-01 DOI: 10.18502/ijhoscr.v18i4.16758
Rashmi Bhardwaj, Lalit Kumar, Deepika Chhabra, Atul Sharma, Sujata Mohanty, Narinder Mehra, Vinod Kochupillai

Background: Human fetal liver hematopoietic stem cells have proven potential as therapeutics but lack extensive research due to their limited supply. Even in vitro expanded fetal liver hematopoietic stem cells enter senescence or lose their self-renewal capacity after a few days in culture. The present study aimed to obtain a homogeneous and persistent supply of hematopoietic stem cells from the fetal liver by establishing a cell line through immortalization of cells by enhancing telomerase activity. Materials and Methods: Human fetal liver hematopoietic CD34+ stem and progenitor cells were transformed and immortalized using retroviruses carrying the human telomerase (hTERT) gene. Following transduction, telomerase activity was assessed using the TRAP assay and telomere length was examined by Southern blotting in transduced cells. Their characterization was conducted using flowcytometry to analyze the CD34+ population of hematopoietic stem cells and their colony forming potential using colony forming unit (CFU) assay. Results: After transduction with hTERT, the life span of human fetal liver hematopoietic CD34+ stem and progenitor cells were extended to 80 population doublings, without any change in cell morphology or population doubling times. Constitutive hTERT expression enhanced the replicative capacity and prevented terminal differentiation of CD34+ fetal liver hematopoietic stem and progenitor cells (FLHSPCs). Moreover, hTERT-transduced stem cells maintained their telomere length and telomerase activity. Conclusion: By introducing telomerase activity into hematopoietic stem and progenitor cells, their lifespan can be extended while maintaining stemness. These modified cells hold promise for in vitro research focused on studying hematopoietic stem cells derived from fetal liver.

背景:人胎肝造血干细胞已被证明具有治疗潜力,但由于其供应有限,缺乏广泛的研究。即使体外扩增的胎肝造血干细胞在培养几天后也会进入衰老或失去自我更新能力。本研究旨在通过提高端粒酶活性,通过细胞永生化建立细胞系,从胎儿肝脏获得均匀和持续的造血干细胞供应。材料与方法:利用携带人端粒酶(hTERT)基因的逆转录病毒对人胎肝造血CD34+干细胞和祖细胞进行转化和永生化。转导后,端粒酶活性用TRAP法评估,端粒长度用Southern印迹法检测。利用流式细胞术分析造血干细胞的CD34+群体,并利用集落形成单位(CFU)法分析其集落形成潜力。结果:经hTERT转导后,人胎肝造血CD34+干细胞和祖细胞寿命延长至80倍,细胞形态和群体倍数未发生变化。组成型hTERT表达增强了CD34+胎肝造血干细胞和祖细胞(FLHSPCs)的复制能力,并阻止了其终末分化。此外,htert转导的干细胞保持了端粒长度和端粒酶活性。结论:在造血干细胞和祖细胞中引入端粒酶活性,可以延长造血干细胞和祖细胞的寿命,同时保持造血干细胞的干性。这些经过修饰的细胞有望用于体外研究,重点是研究来自胎儿肝脏的造血干细胞。
{"title":"Transduction of Human Fetal Liver Hematopoietic CD34+ Stem and Progenitor Cells into a Cell Line by Enhancing Telomerase Activity.","authors":"Rashmi Bhardwaj, Lalit Kumar, Deepika Chhabra, Atul Sharma, Sujata Mohanty, Narinder Mehra, Vinod Kochupillai","doi":"10.18502/ijhoscr.v18i4.16758","DOIUrl":"10.18502/ijhoscr.v18i4.16758","url":null,"abstract":"<p><p><b>Background</b>: Human fetal liver hematopoietic stem cells have proven potential as therapeutics but lack extensive research due to their limited supply. Even <i>in vitro</i> expanded fetal liver hematopoietic stem cells enter senescence or lose their self-renewal capacity after a few days in culture. The present study aimed to obtain a homogeneous and persistent supply of hematopoietic stem cells from the fetal liver by establishing a cell line through immortalization of cells by enhancing telomerase activity. <b>Materials and Methods</b>: Human fetal liver hematopoietic CD34+ stem and progenitor cells were transformed and immortalized using retroviruses carrying the human telomerase (hTERT) gene. Following transduction, telomerase activity was assessed using the TRAP assay and telomere length was e<i>x</i>amined by Southern blotting in transduced cells. Their characterization was conducted using flowcytometry to analyze the CD34+ population of hematopoietic stem cells and their colony forming potential using colony forming unit (CFU) assay. <b>Results</b>: After transduction with hTERT, the life span of human fetal liver hematopoietic CD34+ stem and progenitor cells were extended to 80 population doublings, without any change in cell morphology or population doubling times. Constitutive hTERT expression enhanced the replicative capacity and prevented terminal differentiation of CD34+ fetal liver hematopoietic stem and progenitor cells (FLHSPCs). Moreover, hTERT-transduced stem cells maintained their telomere length and telomerase activity. <b>Conclusion:</b> By introducing telomerase activity into hematopoietic stem and progenitor cells, their lifespan can be extended while maintaining stemness. These modified cells hold promise for <i>in</i> <i>vitro</i> research focused on studying hematopoietic stem cells derived from fetal liver.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"18 4","pages":"330-343"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge and Attitudes of Faculty of Health Sciences Students towards Hematopoietic Stem Cell Donation. 健康科学学院学生对造血干细胞捐献的知识和态度。
Pub Date : 2024-10-01 DOI: 10.18502/ijhoscr.v18i4.16761
Ramazan Çiçek, Ayten Dinç

Background: Hematopoietic stem cell transplantation is a life-saving treatment method for numerous diseases. This study aims to determine the knowledge and attitudes of Faculty of Health Sciences students in a university towards hematopoietic stem cell donation and descriptive cross-sectional design. Materials and Methods:  The study participants consisted of students studying at the Faculty of Health Sciences of a university in western Turkey. A total of 345 students were available to complete a survey. The data were collected online through the Google Form. Data were analyzed using the SPSS 25 program (IBM Corp.; Armonk, NY, USA). Moreover, the Chi-square test, independent samples t-test, and one-way ANOVA were used in this study. Results:  25.2% were registered at "The Turkish Stem Cell Coordination Center", and 89.1% of the unregistered ones wanted to be a stem cell donor. The university students had a moderate level of knowledge about stem cell donation. While the participants were more knowledgeable about stem cell collection with the peripheral method, they had poor knowledge of stem cell collection methods from the bone marrow and stem cell donation processes. There was a significant correlation between the students' level of knowledge about hematopoietic stem cell donation and their university year, occupation, age, graduate school, and parents' educational level (p<0.05). Conclusion:  In this study, it was found that the university students had insufficient knowledge on hematopoietic stem cell donation and their intention to donate stem cells was high.  Holding training sessions, seminars, and conferences for university students as future health professionals to raise their awareness of stem cell donation is recommended.  The fact that new-generation health professionals are sensitive and educated about stem cell donation can contribute to increasing stem cell donations in society.

背景:造血干细胞移植是挽救许多疾病生命的治疗方法。本研究旨在探讨某大学健康科学学院学生对造血干细胞捐献的认知与态度,并采用描述性横断面设计。材料和方法:研究参与者包括在土耳其西部一所大学健康科学学院学习的学生。共有345名学生参与了调查。数据通过谷歌表格在线收集。数据分析使用SPSS 25程序(IBM Corp.;阿蒙克,纽约州,美国)。本研究采用卡方检验、独立样本t检验和单因素方差分析。结果:25.2%的人在“土耳其干细胞协调中心”登记,89.1%的未登记者希望成为干细胞供体。大学生对干细胞捐献的了解程度一般。虽然参与者对外周法的干细胞收集有更多的了解,但他们对骨髓干细胞收集方法和干细胞捐赠过程的了解很少。大学生造血干细胞捐献知识水平与其大学年级、职业、年龄、研究生院、父母文化程度存在显著相关(p结论:本研究发现大学生造血干细胞捐献知识不足,捐献意愿高。建议为未来的卫生专业人员举办培训课程、研讨会和会议,以提高他们对干细胞捐赠的认识。新一代卫生专业人员对干细胞捐赠敏感并受过教育,这一事实有助于增加社会上的干细胞捐赠。
{"title":"Knowledge and Attitudes of Faculty of Health Sciences Students towards Hematopoietic Stem Cell Donation.","authors":"Ramazan Çiçek, Ayten Dinç","doi":"10.18502/ijhoscr.v18i4.16761","DOIUrl":"10.18502/ijhoscr.v18i4.16761","url":null,"abstract":"<p><p><b>Background:</b> Hematopoietic stem cell transplantation is a life-saving treatment method for numerous diseases. This study aims to determine the knowledge and attitudes of Faculty of Health Sciences students in a university towards hematopoietic stem cell donation and descriptive cross-sectional design. <b>Materials and Methods:</b>  The study participants consisted of students studying at the Faculty of Health Sciences of a university in western Turkey. A total of 345 students were available to complete a survey. The data were collected online through the Google Form. Data were analyzed using the SPSS 25 program (IBM Corp.; Armonk, NY, USA). Moreover, the Chi-square test, independent samples t-test, and one-way ANOVA were used in this study. <b>Results: </b> 25.2% were registered at \"The Turkish Stem Cell Coordination Center\", and 89.1% of the unregistered ones wanted to be a stem cell donor. The university students had a moderate level of knowledge about stem cell donation. While the participants were more knowledgeable about stem cell collection with the peripheral method, they had poor knowledge of stem cell collection methods from the bone marrow and stem cell donation processes. There was a significant correlation between the students' level of knowledge about hematopoietic stem cell donation and their university year, occupation, age, graduate school, and parents' educational level (p<0.05). <b>Conclusion: </b> In this study, it was found that the university students had insufficient knowledge on hematopoietic stem cell donation and their intention to donate stem cells was high.  Holding training sessions, seminars, and conferences for university students as future health professionals to raise their awareness of stem cell donation is recommended.  The fact that new-generation health professionals are sensitive and educated about stem cell donation can contribute to increasing stem cell donations in society.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"18 4","pages":"367-376"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series 接种 COVID-19 疫苗后出现再生障碍性贫血:病例报告和病例系列的系统回顾
Pub Date : 2024-07-23 DOI: 10.18502/ijhoscr.v18i3.16111
Nelson Luis Cahuapaza-Gutierrez, Tsuriel Sofía Campos-Escalante
Aplastic anemia (AA) is the prototypical bone marrow failure syndrome due to the destruction of hematopoietic stem cells by cytotoxic T cells. According to case reports, vaccines could lead to the development of AA. We conducted the present systematic review to evaluate cases of AA following vaccination against coronavirus disease (COVID-19). We searched the following databases: PubMed, Scopus, and EMBASE in English, Portuguese, and Spanish languages until April 24, 2023. Published reports and case series on the occurrence of AA following vaccination against COVID-19 were included. The Joanna Brigs Institute was used to assess study quality and risk of bias. Six studies were selected from 102 research studies and data were extracted according to the inclusion criteria. All case reports and case series reported the occurrence of AA following COVID-19 vaccination. AA events were mainly observed in vaccines with messenger ribonucleic acid technology (Moderna; Pfizer-BioNTech). AA was diagnosed by bone marrow biopsy and severity was determined by Camitta criteria. All cases of AA were properly diagnosed. The sample size was small; therefore, further investigations are required to demonstrate and elucidate the complete pathophysiological mechanisms of AA development after receiving COVID-19 vaccination.
再生障碍性贫血(AA)是由于细胞毒性 T 细胞破坏造血干细胞而导致的典型骨髓衰竭综合征。根据病例报告,疫苗可能导致再生障碍性贫血的发生。我们进行了本系统综述,以评估接种冠状病毒病(COVID-19)疫苗后出现 AA 的病例。我们检索了以下数据库:PubMed、Scopus 和 EMBASE(英文、葡萄牙文和西班牙文),检索时间截至 2023 年 4 月 24 日。纳入了有关接种 COVID-19 疫苗后发生 AA 的已发表报告和系列病例。乔安娜-布里格斯研究所(Joanna Brigs Institute)用于评估研究质量和偏倚风险。从 102 项研究中筛选出 6 项研究,并根据纳入标准提取了数据。所有病例报告和系列病例都报告了接种 COVID-19 疫苗后发生 AA 的情况。AA事件主要出现在采用信使核糖核酸技术(Moderna;辉瑞生物技术公司)的疫苗中。AA通过骨髓活检确诊,严重程度根据卡米塔标准确定。所有 AA 病例均得到正确诊断。由于样本量较小,因此还需要进一步的研究来证明和阐明接种 COVID-19 疫苗后 AA 发病的完整病理生理机制。
{"title":"Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series","authors":"Nelson Luis Cahuapaza-Gutierrez, Tsuriel Sofía Campos-Escalante","doi":"10.18502/ijhoscr.v18i3.16111","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16111","url":null,"abstract":"Aplastic anemia (AA) is the prototypical bone marrow failure syndrome due to the destruction of hematopoietic stem cells by cytotoxic T cells. According to case reports, vaccines could lead to the development of AA. We conducted the present systematic review to evaluate cases of AA following vaccination against coronavirus disease (COVID-19). \u0000We searched the following databases: PubMed, Scopus, and EMBASE in English, Portuguese, and Spanish languages until April 24, 2023. Published reports and case series on the occurrence of AA following vaccination against COVID-19 were included. The Joanna Brigs Institute was used to assess study quality and risk of bias. \u0000Six studies were selected from 102 research studies and data were extracted according to the inclusion criteria. All case reports and case series reported the occurrence of AA following COVID-19 vaccination. AA events were mainly observed in vaccines with messenger ribonucleic acid technology (Moderna; Pfizer-BioNTech). AA was diagnosed by bone marrow biopsy and severity was determined by Camitta criteria. \u0000All cases of AA were properly diagnosed. The sample size was small; therefore, further investigations are required to demonstrate and elucidate the complete pathophysiological mechanisms of AA development after receiving COVID-19 vaccination.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"58 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141813217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response-Based Approach for Pediatric Hodgkin Lymphoma in Nations with Restricted Resources 在资源有限的国家采用基于反应的方法治疗小儿霍奇金淋巴瘤
Pub Date : 2024-07-23 DOI: 10.18502/ijhoscr.v18i3.16110
Usama Al‐Jumaily, Hamid D. Habeeb Rjeib, Sabah Al-Mosawy, Safa Faraj, Monika Metzger
Background: Hodgkin lymphoma (HL) management varies throughout developing nations. This observational study aims to present the results of children having HL who received various combinations of chemotherapy treatment. The response-based method was used regardless of the risk classification. Materials and Methods: We recruited patients≤ 18 years of age diagnosed with HL in an Iraqi cancer center between January 2014 and December 2021. By stratifying patients, three risk categories were identified. Every patient initially received two cycles of ABVD as induction chemotherapy. Following induction chemotherapy, patients showing a full radiological response continued on ABVD chemotherapy for 4-6 cycles without receiving radiotherapy. Patients showing a modest initial response received three additional courses of COPDac next to the third cycle of ABVD, followed by radiotherapy. Results: This study included fifty-nine patients with a median age of 7 years. Stage III patients accounted for 33.9% (n=20), then stage II (32.2%). B symptoms were present in 25 patients. Eleven children had initial splenic involvement. Fifty-two individuals (n = 19; 32.2%) had bulky disease. Mixed cellularity was the most prevalent histology (n=44). The median duration of follow-up was 2.7 years. EFS was 78% ±10%, and survival was 92% at 5-year estimation. Bulky disease was the only factor with a substantial unfavorable impact on the result. Conclusion: Response-based approach is a valuable strategy in nations with limited resources to prevent long-term sequelae from unnecessary radiotherapy.   
背景:发展中国家对霍奇金淋巴瘤(HL)的治疗各不相同。本观察性研究旨在介绍接受各种化疗组合的霍奇金淋巴瘤患儿的治疗结果。无论风险分类如何,均采用基于反应的方法。材料和方法:我们招募了 2014 年 1 月至 2021 年 12 月期间在伊拉克一家癌症中心确诊为 HL 的 18 岁以下患者。通过对患者进行分层,确定了三个风险类别。每位患者首先接受两个周期的 ABVD 诱导化疗。诱导化疗后,出现完全放射学反应的患者继续接受4-6个周期的ABVD化疗,但不接受放疗。初始反应轻微的患者在接受第三个周期的ABVD化疗后,再接受三个疗程的COPDac化疗,然后接受放疗。研究结果本研究共纳入 59 名患者,中位年龄为 7 岁。III 期患者占 33.9%(20 人),其次是 II 期(32.2%)。25名患者出现B症状。有 11 名儿童最初受累于脾脏。52名患者(n=19;32.2%)有大块病变。混合细胞性是最常见的组织形态(n=44)。中位随访时间为2.7年。有效生存率为78%±10%,5年估计生存率为92%。大块病变是对结果产生重大不利影响的唯一因素。结论在资源有限的国家,以反应为基础的方法是防止不必要的放疗造成长期后遗症的重要策略。
{"title":"Response-Based Approach for Pediatric Hodgkin Lymphoma in Nations with Restricted Resources","authors":"Usama Al‐Jumaily, Hamid D. Habeeb Rjeib, Sabah Al-Mosawy, Safa Faraj, Monika Metzger","doi":"10.18502/ijhoscr.v18i3.16110","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16110","url":null,"abstract":"Background: Hodgkin lymphoma (HL) management varies throughout developing nations. This observational study aims to present the results of children having HL who received various combinations of chemotherapy treatment. The response-based method was used regardless of the risk classification. \u0000Materials and Methods: We recruited patients≤ 18 years of age diagnosed with HL in an Iraqi cancer center between January 2014 and December 2021. By stratifying patients, three risk categories were identified. Every patient initially received two cycles of ABVD as induction chemotherapy. Following induction chemotherapy, patients showing a full radiological response continued on ABVD chemotherapy for 4-6 cycles without receiving radiotherapy. Patients showing a modest initial response received three additional courses of COPDac next to the third cycle of ABVD, followed by radiotherapy. \u0000Results: This study included fifty-nine patients with a median age of 7 years. Stage III patients accounted for 33.9% (n=20), then stage II (32.2%). B symptoms were present in 25 patients. Eleven children had initial splenic involvement. Fifty-two individuals (n = 19; 32.2%) had bulky disease. Mixed cellularity was the most prevalent histology (n=44). The median duration of follow-up was 2.7 years. EFS was 78% ±10%, and survival was 92% at 5-year estimation. Bulky disease was the only factor with a substantial unfavorable impact on the result. \u0000Conclusion: Response-based approach is a valuable strategy in nations with limited resources to prevent long-term sequelae from unnecessary radiotherapy.   ","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"143 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141810832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unleashing the Impact of Exosomes Derived from Human Placental Mesenchymal Stem Cells (hPMSCs) on U-266 Myeloma Cell Line 释放人胎盘间充质干细胞(hPMSCs)外泌体对 U-266 骨髓瘤细胞系的影响
Pub Date : 2024-07-23 DOI: 10.18502/ijhoscr.v18i3.16109
Ayda Baghery Saghchy Khorasani, Mina Soufizomorrod, Davood Bashash
Multiple myeloma (MM) is a malignancy of plasma cells, terminally differentiated B cells, with complications like hypercalcemia, renal failure, anemia, and bone disease, which are also known as CRAB criteria. MM develops from monoclonal gammopathy of unknown significance (MGUS), a pre-malignant plasma cell dyscrasia. Over some time, MGUS has the potential to progress into smoldering multiple myeloma (SMM), which can evolve into MM. MM rarely progresses into plasma cell leukemia (PCL), a condition in which malignant plasma cells no longer stay in the bone marrow niche and circulate in the peripheral blood. In MM, various soluble factors play important roles, and interleukin-6 has different vital roles.  Interleukin-6, an inflammatory cytokine, has significant roles in the growth, survival, angiogenesis, metastasis, and apoptosis resistance in MM. Interleukin-6 is produced and secreted by both autocrine from myeloma cells and paracrine from bone marrow stromal cells. To tackle MM, various therapeutic approaches were applied over many years, and according to the results, most patients with MM can respond well to first-line treatment. However, the majority of patients may relapse as conventional treatment may not be curative. So, there is an urgent need for novel cell-based and cell-free therapeutic strategies, such as mesenchymal stem cell-based therapies and their products to offer new therapeutic strategies for MM. Materials and Methods: In the present study, we investigated the impacts of exosomes derived from human placental mesenchymal stem cells (hPMSCs) on apoptosis and interleukin-6 expression in a myeloma cell line, U-266, for the first time. hPMSCs were isolated from the human placenta and cultured in a DMEM medium. After characterizing the cells and acknowledging their identity, they underwent several passages and their supernatant was collected to harvest exosomes. The exosomes were isolated by ultracentrifugation and characterized by DLS and TEM, and their concentration was measured by BCA protein assay. U266 cells were treated with different concentrations of exosomes and then MTT and annexin/propidium iodide flow cytometry tests were performed to evaluate cell viability. Afterward, a real-time PCR test was performed to evaluate interleukin-6 gene expression. Results: According to our findings, treatment of U-266 cells with hPMSCS-derived exosomes led to the preservation of myeloma cells without changes in their cell cycle. Surprisingly, treatments did not hinder the expression of interleukin-6 in the myeloma cells. Conclusion: In MM patients, interleukin-6 plays different roles, and it is a desirable target to design new therapeutic strategies. To evaluate the effects of new therapeutic strategies, we designed and performed our study to estimate the effects of cell-free therapeutic strategy.  In the present study, the impacts of hPMSCS-derived exosomes on the viability of MM cells and interleukin-6 gene expression were evaluated.
多发性骨髓瘤(MM)是一种浆细胞(终末分化的 B 细胞)恶性肿瘤,具有高钙血症、肾功能衰竭、贫血和骨病等并发症,这也被称为 CRAB 标准。MM 是由意义不明的单克隆丙种球蛋白病(MGUS)发展而来的,MGUS 是一种恶性前浆细胞异常。经过一段时间后,MGUS 有可能发展为烟雾型多发性骨髓瘤(SMM),SMM 又可能发展为 MM。MM很少发展为浆细胞白血病(PCL),在这种情况下,恶性浆细胞不再停留在骨髓龛中,而是在外周血中循环。在 MM 中,各种可溶性因子发挥着重要作用,其中白细胞介素-6 发挥着不同的重要作用。 白细胞介素-6 是一种炎性细胞因子,在 MM 的生长、存活、血管生成、转移和抗凋亡中起着重要作用。白细胞介素-6通过骨髓瘤细胞的自分泌和骨髓基质细胞的旁分泌产生和分泌。针对骨髓瘤,多年来人们采用了多种治疗方法,结果表明,大多数骨髓瘤患者对一线治疗反应良好。不過,由於傳統治療未必能根治,大部分病人可能會復發。因此,迫切需要新型的细胞和无细胞治疗策略,如间充质干细胞疗法及其产品,为 MM 提供新的治疗策略。材料与方法:在本研究中,我们首次研究了从人胎盘间充质干细胞(hPMSCs)中提取的外泌体对骨髓瘤细胞系U-266的细胞凋亡和白细胞介素-6表达的影响。在确定细胞特征并确认其身份后,对其进行了多次传代,并收集其上清液以收获外泌体。通过超速离心法分离外泌体,用 DLS 和 TEM 对其进行表征,并用 BCA 蛋白检测法测定其浓度。用不同浓度的外泌体处理 U266 细胞,然后用 MTT 和附件素/碘化丙啶流式细胞术检测细胞活力。之后,进行实时 PCR 检测以评估白细胞介素-6 基因的表达。结果根据我们的研究结果,用源自 hPMSCS 的外泌体处理 U-266 细胞可保存骨髓瘤细胞,且细胞周期不会发生变化。令人惊讶的是,治疗并未阻碍骨髓瘤细胞中白细胞介素-6的表达。结论是在 MM 患者体内,白细胞介素-6 发挥着不同的作用,是设计新治疗策略的理想靶点。为了评估新治疗策略的效果,我们设计并开展了无细胞治疗策略的效果评估研究。 本研究评估了源自 hPMSCS 的外泌体对 MM 细胞活力和白细胞介素-6 基因表达的影响。结果表明,hPMSCS衍生的外泌体可使骨髓瘤细胞存活下来,而细胞周期不会发生变化。 此外,白细胞介素-6基因表达水平也没有发生显著变化。
{"title":"Unleashing the Impact of Exosomes Derived from Human Placental Mesenchymal Stem Cells (hPMSCs) on U-266 Myeloma Cell Line","authors":"Ayda Baghery Saghchy Khorasani, Mina Soufizomorrod, Davood Bashash","doi":"10.18502/ijhoscr.v18i3.16109","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16109","url":null,"abstract":"Multiple myeloma (MM) is a malignancy of plasma cells, terminally differentiated B cells, with complications like hypercalcemia, renal failure, anemia, and bone disease, which are also known as CRAB criteria. MM develops from monoclonal gammopathy of unknown significance (MGUS), a pre-malignant plasma cell dyscrasia. Over some time, MGUS has the potential to progress into smoldering multiple myeloma (SMM), which can evolve into MM. MM rarely progresses into plasma cell leukemia (PCL), a condition in which malignant plasma cells no longer stay in the bone marrow niche and circulate in the peripheral blood. In MM, various soluble factors play important roles, and interleukin-6 has different vital roles. \u0000 Interleukin-6, an inflammatory cytokine, has significant roles in the growth, survival, angiogenesis, metastasis, and apoptosis resistance in MM. Interleukin-6 is produced and secreted by both autocrine from myeloma cells and paracrine from bone marrow stromal cells. To tackle MM, various therapeutic approaches were applied over many years, and according to the results, most patients with MM can respond well to first-line treatment. However, the majority of patients may relapse as conventional treatment may not be curative. So, there is an urgent need for novel cell-based and cell-free therapeutic strategies, such as mesenchymal stem cell-based therapies and their products to offer new therapeutic strategies for MM. \u0000Materials and Methods: In the present study, we investigated the impacts of exosomes derived from human placental mesenchymal stem cells (hPMSCs) on apoptosis and interleukin-6 expression in a myeloma cell line, U-266, for the first time. hPMSCs were isolated from the human placenta and cultured in a DMEM medium. After characterizing the cells and acknowledging their identity, they underwent several passages and their supernatant was collected to harvest exosomes. The exosomes were isolated by ultracentrifugation and characterized by DLS and TEM, and their concentration was measured by BCA protein assay. U266 cells were treated with different concentrations of exosomes and then MTT and annexin/propidium iodide flow cytometry tests were performed to evaluate cell viability. Afterward, a real-time PCR test was performed to evaluate interleukin-6 gene expression. \u0000Results: According to our findings, treatment of U-266 cells with hPMSCS-derived exosomes led to the preservation of myeloma cells without changes in their cell cycle. Surprisingly, treatments did not hinder the expression of interleukin-6 in the myeloma cells. \u0000Conclusion: In MM patients, interleukin-6 plays different roles, and it is a desirable target to design new therapeutic strategies. To evaluate the effects of new therapeutic strategies, we designed and performed our study to estimate the effects of cell-free therapeutic strategy.  In the present study, the impacts of hPMSCS-derived exosomes on the viability of MM cells and interleukin-6 gene expression were evaluated. ","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"3 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141813722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclophosphamide- Antifungals Interactions in Patients Undergoing Hematopoietic Stem Cell Transplantation: What Should We Know About it? 环磷酰胺与抗真菌药物在造血干细胞移植患者中的相互作用:我们应该了解什么?
Pub Date : 2024-07-23 DOI: 10.18502/ijhoscr.v18i3.16112
Sogol Zarrabi, Mohammad Vaezi, B. Shahrami
The Article Abstract is not available.
文章摘要不详。
{"title":"Cyclophosphamide- Antifungals Interactions in Patients Undergoing Hematopoietic Stem Cell Transplantation: What Should We Know About it?","authors":"Sogol Zarrabi, Mohammad Vaezi, B. Shahrami","doi":"10.18502/ijhoscr.v18i3.16112","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16112","url":null,"abstract":"The Article Abstract is not available.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"89 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141812726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between Breast Cancer and Cardiac Myxoma 乳腺癌与心脏肌瘤的关系
Pub Date : 2024-07-23 DOI: 10.18502/ijhoscr.v18i3.16113
Nur Hürsoy, Merve Solak, Demet Nak
The Article Abstract is not available.
文章摘要不详。
{"title":"Relationship between Breast Cancer and Cardiac Myxoma","authors":"Nur Hürsoy, Merve Solak, Demet Nak","doi":"10.18502/ijhoscr.v18i3.16113","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16113","url":null,"abstract":"The Article Abstract is not available.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"136 52","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141811046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological, Demographic, and Clinical Characteristics of Von Willebrand Disease Patients in Zahedan City, Iran: A Descriptive Study 伊朗扎黑丹市冯-威廉布兰德病患者的流行病学、人口统计学和临床特征:描述性研究
Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16102
Majid Naderi, Benyamin Rhmati, Hoora Ganjali, Saeedeh Yaghoubi, Mohammad Sadra Harifi-Mood, Seyed Ghader Azizi
Background: Von Willebrand disease (VWD) is one of the most common coagulative diseases, so identifying the effective factors in preventing this complication is essential. The study aimed to evaluate the frequency of demographic and epidemiological findings in VWD patients referred to a hospital in Zahedan, Iran. Materials and Methods: This study was performed on 76 patients with VWD referred to Hazrat Ali-Asghar Hospital in Zahedan City, Sistan, and Baluchestan province. After obtaining consent from the patients, the demographic information and clinical symptoms of the disease were recorded. All statistical analyses were performed using SPSS 22.0 software. All descriptive data were expressed as mean ±SD and percent (%) depending on the continuous and dichotomous variables. A P-value ≤0.05 was considered significant statistically. Results: The present study results showed that the highest age group of VWD patients at the time of disease diagnosis was in the age group 1-5 years (47.3%), and most patients had type III VWD (80.3%). It was also found that 67.1% of patients had a positive family history and their parents' consanguineous marriage (77.6%). The most common complaints were epistaxis (88.15%), cutaneous bleeding (78.94%), and oral cavity bleeding (61.84%), respectively. Conclusion: Due to the high prevalence of VWD in consanguineous marriages and an increase in adverse complications and symptoms in VWD patients, proper diagnosis and screening at an early age, especially in people with family history, is essential. Efforts are needed to develop national registries and widely provide the required and available basic services for diagnosis and treatment.  
背景:冯-威廉氏病(VWD)是最常见的凝血疾病之一,因此确定预防这种并发症的有效因素至关重要。本研究旨在评估转诊至伊朗扎黑丹一家医院的 VWD 患者的人口统计学和流行病学发现的频率。材料和方法:研究对象为转诊至锡斯坦和俾路支斯坦省扎黑丹市 Hazrat Ali-Asghar 医院的 76 名 VWD 患者。在征得患者同意后,对其人口统计学信息和临床症状进行了记录。所有统计分析均使用 SPSS 22.0 软件进行。根据连续变量和二分变量,所有描述性数据均以均数±SD和百分比(%)表示。P值≤0.05被认为具有统计学意义。结果本研究结果显示,1-5 岁是 VWD 患者确诊时的最高年龄组(47.3%),大多数患者为 III 型 VWD(80.3%)。研究还发现,67.1%的患者有阳性家族史,其父母为近亲结婚(77.6%)。最常见的主诉分别是鼻衄(88.15%)、皮肤出血(78.94%)和口腔出血(61.84%)。结论由于 VWD 在近亲结婚中的高发病率以及 VWD 患者不良并发症和症状的增加,因此在早期进行适当的诊断和筛查至关重要,尤其是对有家族史的人群。需要努力建立国家登记册,广泛提供诊断和治疗所需的基本服务。
{"title":"Epidemiological, Demographic, and Clinical Characteristics of Von Willebrand Disease Patients in Zahedan City, Iran: A Descriptive Study","authors":"Majid Naderi, Benyamin Rhmati, Hoora Ganjali, Saeedeh Yaghoubi, Mohammad Sadra Harifi-Mood, Seyed Ghader Azizi","doi":"10.18502/ijhoscr.v18i3.16102","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16102","url":null,"abstract":"Background: Von Willebrand disease (VWD) is one of the most common coagulative diseases, so identifying the effective factors in preventing this complication is essential. The study aimed to evaluate the frequency of demographic and epidemiological findings in VWD patients referred to a hospital in Zahedan, Iran. \u0000Materials and Methods: This study was performed on 76 patients with VWD referred to Hazrat Ali-Asghar Hospital in Zahedan City, Sistan, and Baluchestan province. After obtaining consent from the patients, the demographic information and clinical symptoms of the disease were recorded. All statistical analyses were performed using SPSS 22.0 software. All descriptive data were expressed as mean ±SD and percent (%) depending on the continuous and dichotomous variables. A P-value ≤0.05 was considered significant statistically. \u0000Results: The present study results showed that the highest age group of VWD patients at the time of disease diagnosis was in the age group 1-5 years (47.3%), and most patients had type III VWD (80.3%). It was also found that 67.1% of patients had a positive family history and their parents' consanguineous marriage (77.6%). The most common complaints were epistaxis (88.15%), cutaneous bleeding (78.94%), and oral cavity bleeding (61.84%), respectively. \u0000Conclusion: Due to the high prevalence of VWD in consanguineous marriages and an increase in adverse complications and symptoms in VWD patients, proper diagnosis and screening at an early age, especially in people with family history, is essential. Efforts are needed to develop national registries and widely provide the required and available basic services for diagnosis and treatment. \u0000 ","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"62 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141817630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluate the Efficacy of Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia at BTH, Vietnam 在越南 BTH 评估急性髓性白血病异基因造血干细胞移植中髓鞘剥脱治疗方案的疗效
Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16106
T. Nguyen, Huu Than Huynh, Hung Quang Tran, Quang The Nguyen, P. Huynh, Nam Duy Hoang, Tuan Xuan Ma, Duong Thi Thuy Do, Dung Chi Phu, Man Van Huynh
Background: Busulfan plus cyclophosphamide (Bu/Cy) is considered one of the classical myeloablative conditioning regimens. However, its toxicity can significantly increase mortality rates. To reduce both acute and long-term complications after hematopoietic stem cell transplantation (HSCT), newer conditioning regimens are being investigated. The purposes of this study were to assess the efficacy and safety of busulfan plus cyclophosphamide (Bu/Cy) and busulfan plus fludarabine (Bu/Flu) conditioning regimen for allogeneic HSCT (allo-HSCT) in acute myelogenous leukemia (AML). Materials and Methods: We conducted a single-center, retrospective analysis of AML, both adults and children, who underwent either Bu/Cy or Bu/Flu conditioning regimen for allo-HSCT and received peripheral blood stem cell transplants from HLA-matched donors. Results: From 2005 – 2019, 49 AML patients receiving Bu/Cy and 21 receiving Bu/Flu were identified, meeting inclusion criteria. The two groups showed no significant differences in age, gender, disease status pre-transplant, the median time to neutrophil and platelet engraftment. Bu/Flu patients had a shorter duration of neutropenia (median 7 days vs 10 days, p = 0.001) and shorter duration of thrombocytopenia (median 10 days vs 15 days, p = 0.016) than Bu/Cy.  No difference was observed in disease-free survival (DFS) and overall survival (OS) between the two groups. Both univariate and multivariate analyses showed that age, disease status pre-transplant, and chronic graft-versus-host disease (GvHD) are related to worse DFS and OS. Conclusion: With similar efficacy to Bu/Cy but faster neutrophil and platelet recovery time, Bu/Flu is suitable as a pre-HSCT conditioning regimen for patients with AML.
背景:布舒凡加环磷酰胺(Bu/Cy)被认为是经典的髓鞘消融治疗方案之一。然而,其毒性会大大增加死亡率。为了减少造血干细胞移植(HSCT)后的急性和长期并发症,目前正在研究更新的调理方案。本研究的目的是评估急性髓性白血病(AML)异基因造血干细胞移植(allo-HSCT)中布鲁班加环磷酰胺(Bu/Cy)和布鲁班加氟达拉滨(Bu/Flu)调理方案的有效性和安全性。材料与方法:我们对接受Bu/Cy或Bu/Flu调理方案进行异基因造血干细胞移植并接受HLA匹配供者外周血干细胞移植的成人和儿童急性髓性白血病患者进行了单中心回顾性分析。研究结果从 2005 年到 2019 年,符合纳入标准的急性髓细胞性白血病患者中有 49 人接受了 Bu/Cy 方案,21 人接受了 Bu/Flu 方案。两组患者在年龄、性别、移植前疾病状态、中性粒细胞和血小板移植中位时间等方面无明显差异。与 Bu/Cy 相比,Bu/Flu 患者的中性粒细胞减少持续时间更短(中位数为 7 天 vs 10 天,p = 0.001),血小板减少持续时间更短(中位数为 10 天 vs 15 天,p = 0.016)。 两组患者的无病生存期(DFS)和总生存期(OS)没有差异。单变量和多变量分析表明,年龄、移植前疾病状态和慢性移植物抗宿主病(GvHD)与较差的无病生存期和总生存期有关。结论Bu/Flu的疗效与Bu/Cy相似,但中性粒细胞和血小板恢复时间更快,适合作为急性髓细胞白血病患者的HSCT前调理方案。
{"title":"Evaluate the Efficacy of Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia at BTH, Vietnam","authors":"T. Nguyen, Huu Than Huynh, Hung Quang Tran, Quang The Nguyen, P. Huynh, Nam Duy Hoang, Tuan Xuan Ma, Duong Thi Thuy Do, Dung Chi Phu, Man Van Huynh","doi":"10.18502/ijhoscr.v18i3.16106","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16106","url":null,"abstract":"Background: Busulfan plus cyclophosphamide (Bu/Cy) is considered one of the classical myeloablative conditioning regimens. However, its toxicity can significantly increase mortality rates. To reduce both acute and long-term complications after hematopoietic stem cell transplantation (HSCT), newer conditioning regimens are being investigated. The purposes of this study were to assess the efficacy and safety of busulfan plus cyclophosphamide (Bu/Cy) and busulfan plus fludarabine (Bu/Flu) conditioning regimen for allogeneic HSCT (allo-HSCT) in acute myelogenous leukemia (AML). \u0000Materials and Methods: We conducted a single-center, retrospective analysis of AML, both adults and children, who underwent either Bu/Cy or Bu/Flu conditioning regimen for allo-HSCT and received peripheral blood stem cell transplants from HLA-matched donors. \u0000Results: From 2005 – 2019, 49 AML patients receiving Bu/Cy and 21 receiving Bu/Flu were identified, meeting inclusion criteria. The two groups showed no significant differences in age, gender, disease status pre-transplant, the median time to neutrophil and platelet engraftment. Bu/Flu patients had a shorter duration of neutropenia (median 7 days vs 10 days, p = 0.001) and shorter duration of thrombocytopenia (median 10 days vs 15 days, p = 0.016) than Bu/Cy.  No difference was observed in disease-free survival (DFS) and overall survival (OS) between the two groups. Both univariate and multivariate analyses showed that age, disease status pre-transplant, and chronic graft-versus-host disease (GvHD) are related to worse DFS and OS. \u0000Conclusion: With similar efficacy to Bu/Cy but faster neutrophil and platelet recovery time, Bu/Flu is suitable as a pre-HSCT conditioning regimen for patients with AML.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"35 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141818489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of High Intensity Interval Exercise on Platelet Engraftment in Autologous Bone Marrow Transplantation (BMT) 高强度间歇运动对自体骨髓移植(BMT)中血小板移植的影响
Pub Date : 2024-07-21 DOI: 10.18502/ijhoscr.v18i3.16104
Tayebe Zarekar, Abbas Hajifathali, S. Ahmadizad
Background: Thrombocytopenia is a frequent complication after hematopoietic stem cell transplantation (HSCT). Although platelet transfusion is the most used treatment for severe thrombocytopenia, it is associated with well-established risks. High-intensity interval exercise (HIIE) results in thrombocytosis. Therefore, this study aimed to reduce thrombocytopenia by increasing platelet count through exercise. Materials and Methods: Twenty lymphoma and multiple myeloma patients were divided into HIIE and control groups. To determine the maximal exercise capacity, patients in the HIIE group performed a graded exercise test. All patients received granulocyte colony-stimulating factor for 5 days, followed by a HIIE trial. After 5 min warm up at 10 to 20% of peak power, patients in the HIIE group performed an HIIE protocol that included 12 intervals of one-minute work at 100% peak power interspersed by one-minute active rest at 20% of peak power. Patients in the control group were seated for the same duration without any physical activity. Two blood samples were taken before and immediately after the trials and were analyzed for measuring complete blood count. Results: Platelet count on the day of platelet engraftment in the HIIE group was significantly higher than in the control group (P=0.02). Single-donor platelet transfusion was significantly lower in the HIIE group than in the control group (P=0.05). Conclusion: Based on the findings of the present study, a short bout of HIIE had a positive effect on platelet engraftment through thrombocytosis and reduced platelet transfusion and its complications, which could be a useful strategy for HSCT patients.  
背景:血小板减少症是造血干细胞移植(HSCT)后的常见并发症。虽然输注血小板是治疗严重血小板减少症最常用的方法,但它也有公认的风险。高强度间歇运动(HIIE)会导致血小板减少。因此,本研究旨在通过运动增加血小板数量来减少血小板减少症。材料与方法:将 20 名淋巴瘤和多发性骨髓瘤患者分为高强度间歇运动组和对照组。为了确定最大运动能力,HIIE 组患者进行了分级运动测试。所有患者接受粒细胞集落刺激因子治疗 5 天,然后进行 HIIE 试验。在以峰值功率的 10% 至 20% 进行 5 分钟热身后,HIIE 组患者进行 HIIE 方案,包括以峰值功率的 20% 进行 12 次间隔为 1 分钟的 100%运动,中间穿插 1 分钟的主动休息。对照组患者在相同时间内坐着,不做任何体力活动。在试验前和试验后立即采集两次血液样本,并进行分析,以测量全血细胞计数。结果HIIE 组在血小板移植当天的血小板计数明显高于对照组(P=0.02)。HIIE 组的单次血小板输注量明显低于对照组(P=0.05)。结论根据本研究的结果,短时间的 HIIE 通过血小板减少对血小板移植有积极影响,并减少了血小板输注及其并发症,这可能是造血干细胞移植患者的一种有用策略。
{"title":"The effect of High Intensity Interval Exercise on Platelet Engraftment in Autologous Bone Marrow Transplantation (BMT)","authors":"Tayebe Zarekar, Abbas Hajifathali, S. Ahmadizad","doi":"10.18502/ijhoscr.v18i3.16104","DOIUrl":"https://doi.org/10.18502/ijhoscr.v18i3.16104","url":null,"abstract":"Background: Thrombocytopenia is a frequent complication after hematopoietic stem cell transplantation (HSCT). Although platelet transfusion is the most used treatment for severe thrombocytopenia, it is associated with well-established risks. High-intensity interval exercise (HIIE) results in thrombocytosis. Therefore, this study aimed to reduce thrombocytopenia by increasing platelet count through exercise. \u0000Materials and Methods: Twenty lymphoma and multiple myeloma patients were divided into HIIE and control groups. To determine the maximal exercise capacity, patients in the HIIE group performed a graded exercise test. All patients received granulocyte colony-stimulating factor for 5 days, followed by a HIIE trial. After 5 min warm up at 10 to 20% of peak power, patients in the HIIE group performed an HIIE protocol that included 12 intervals of one-minute work at 100% peak power interspersed by one-minute active rest at 20% of peak power. Patients in the control group were seated for the same duration without any physical activity. Two blood samples were taken before and immediately after the trials and were analyzed for measuring complete blood count. \u0000Results: Platelet count on the day of platelet engraftment in the HIIE group was significantly higher than in the control group (P=0.02). Single-donor platelet transfusion was significantly lower in the HIIE group than in the control group (P=0.05). \u0000Conclusion: Based on the findings of the present study, a short bout of HIIE had a positive effect on platelet engraftment through thrombocytosis and reduced platelet transfusion and its complications, which could be a useful strategy for HSCT patients. \u0000 ","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"57 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141817949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of hematology-oncology and stem cell research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1